Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update.
RNA
clinical trial
dendritic cells
electroporation
immunotherapy
therapeutic vaccination
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
23 Jan 2020
23 Jan 2020
Historique:
received:
13
12
2019
revised:
09
01
2020
accepted:
18
01
2020
entrez:
26
1
2020
pubmed:
26
1
2020
medline:
26
1
2020
Statut:
epublish
Résumé
Over the last two decades, dendritic cell (DC) vaccination has been studied extensively as active immunotherapy in cancer treatment and has been proven safe in all clinical trials both with respect to short and long-term side effects. For antigen-loading of dendritic cells (DCs) one method is to introduce mRNA coding for the desired antigens. To target the whole antigenic repertoire of a tumor, even the total tumor mRNA of a macrodissected biopsy sample can be used. To date, reports have been published on a total of 781 patients suffering from different tumor entities and HIV-infection, who have been treated with DCs loaded with mRNA. The majority of those were melanoma patients, followed by HIV-infected patients, but leukemias, brain tumors, prostate cancer, renal cell carcinomas, pancreatic cancers and several others have also been treated. Next to antigen-loading, mRNA-electroporation allows a purposeful manipulation of the DCs' phenotype and function to enhance their immunogenicity. In this review, we intend to give a comprehensive summary of what has been published regarding clinical testing of ex vivo generated mRNA-transfected DCs, with respect to safety and risk/benefit evaluations, choice of tumor antigens and RNA-source, and the design of better DCs for vaccination by transfection of mRNA-encoded functional proteins.
Identifiants
pubmed: 31979205
pii: pharmaceutics12020092
doi: 10.3390/pharmaceutics12020092
pmc: PMC7076681
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Deutsche Krebshilfe
ID : FKZ110182
Organisme : Hasumi International Research Foundation
ID : na
Déclaration de conflit d'intérêts
The authors declare the following potential conflict of interest: G.S., N.S., and J.D. are named as inventors on a patent on caIKK-RNA-electroporated DCs (WO/2012/055551). The funders had no role in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
J Immunother Cancer. 2015 Apr 21;3:14
pubmed: 25901286
Cancer Immunol Immunother. 2016 Mar;65(3):327-39
pubmed: 26861670
Oncoimmunology. 2015 Aug 12;5(2):e1071007
pubmed: 27057436
J Clin Oncol. 2015 Apr 20;33(12):1325-33
pubmed: 25584002
Cancer Immunol Immunother. 2007 May;56(5):659-75
pubmed: 16947019
J Exp Med. 1996 Aug 1;184(2):465-72
pubmed: 8760800
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):878-87
pubmed: 16467102
Cancer Immunol Immunother. 2008 Oct;57(10):1559-68
pubmed: 18618110
Eur Urol. 2018 May;73(5):751-759
pubmed: 29248319
J Exp Med. 1996 Jan 1;183(1):87-97
pubmed: 8551248
Ann Surg. 2002 Apr;235(4):540-9
pubmed: 11923611
Front Immunol. 2019 Aug 08;10:1832
pubmed: 31440238
Prog Exp Tumor Res. 1970;13:1-27
pubmed: 4921480
Melanoma Res. 2007 Oct;17(5):316-22
pubmed: 17885587
Cancer Res. 2018 Jan 1;78(1):256-264
pubmed: 29093005
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643231
Blood. 2002 Mar 1;99(5):1517-26
pubmed: 11861263
Cancer Immunol Immunother. 2009 Jan;58(1):1-14
pubmed: 18719915
Oncoimmunology. 2019 Jul 18;8(11):e1638212
pubmed: 31646087
Immunity. 2017 Aug 15;47(2):221-223
pubmed: 28813655
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319
Nat Med. 2004 Sep;10(9):909-15
pubmed: 15340416
Blood. 2017 Oct 12;130(15):1713-1721
pubmed: 28830889
Nat Med. 1998 Mar;4(3):328-32
pubmed: 9500607
J Exp Med. 2005 May 2;201(9):1503-17
pubmed: 15867097
Nat Rev Cancer. 2012 Mar 22;12(4):265-77
pubmed: 22437871
Clin Cancer Res. 2014 Aug 15;20(16):4228-39
pubmed: 25056373
Clin Cancer Res. 2018 Mar 15;24(6):1315-1325
pubmed: 29301826
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Cancer Invest. 2003;21(6):873-86
pubmed: 14735692
BMC Cancer. 2014 Apr 10;14:251
pubmed: 24720900
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
J Transl Med. 2014 Jun 19;12:175
pubmed: 24947606
Eur J Immunol. 2010 Aug;40(8):2123-30
pubmed: 20853498
Cancer Res. 2003 May 1;63(9):2127-33
pubmed: 12727829
Nat Med. 1995 Dec;1(12):1297-302
pubmed: 7489412
Cytotherapy. 2017 Apr;19(4):500-513
pubmed: 28215654
J Immunother. 2005 Sep-Oct;28(5):505-16
pubmed: 16113607
J Exp Med. 2001 Jan 15;193(2):233-8
pubmed: 11208863
J Leukoc Biol. 2001 Jun;69(6):937-43
pubmed: 11404379
Cancer Res. 2001 Dec 1;61(23):8513-9
pubmed: 11731436
Clin Cancer Res. 2004 May 1;10(9):2944-53
pubmed: 15131029
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Nature. 2010 Jan 14;463(7278):191-6
pubmed: 20016485
Cancer Immunol Immunother. 2004 Jul;53(7):651-8
pubmed: 14999431
Clin Cancer Res. 2002 Apr;8(4):1021-32
pubmed: 11948109
J Clin Oncol. 2013 Dec 1;31(34):4311-8
pubmed: 24145345
AIDS. 2012 Feb 20;26(4):F1-12
pubmed: 22156965
Mol Ther Oncolytics. 2019 Mar 27;13:67-81
pubmed: 31020037
Cancer Gene Ther. 2006 Oct;13(10):905-18
pubmed: 16710345
Oncology. 2019;97(3):135-148
pubmed: 31216557
Ther Adv Med Oncol. 2019 Dec 11;11:1758835919891622
pubmed: 31853267
J Clin Invest. 2013 Jul;123(7):3135-45
pubmed: 23934126
Ann Oncol. 2013 Oct;24(10):2686-93
pubmed: 23904461
J Clin Invest. 2005 Dec;115(12):3623-33
pubmed: 16308572
Oncoimmunology. 2015 Apr 1;4(8):e1019197
pubmed: 26405571
Cancer Res. 2003 Jan 1;63(1):12-7
pubmed: 12517769
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Cancer Res. 2001 Sep 1;61(17):6451-8
pubmed: 11522640
Cold Spring Harb Perspect Biol. 2018 Nov 1;10(11):
pubmed: 29254980
Cancer Immunol Immunother. 2015 Mar;64(3):381-8
pubmed: 25548092
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8
pubmed: 16247014
Br J Cancer. 2005 Oct 3;93(7):749-56
pubmed: 16136047
Cancer Immunol Immunother. 2005 Jul;54(7):663-70
pubmed: 15918076
J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):246-53
pubmed: 26379068
Proc Natl Acad Sci U S A. 2015 Jan 13;112(2):E166-75
pubmed: 25548167
Cancer Immunol Immunother. 2013 Aug;62(8):1381-92
pubmed: 23728352
Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77
pubmed: 16467101
Cancer Res. 2009 Apr 1;69(7):2927-34
pubmed: 19318559
J Exp Med. 1997 Oct 6;186(7):1177-82
pubmed: 9314567
Cancer Invest. 2003 Jun;21(3):341-9
pubmed: 12901279
Curr Top Microbiol Immunol. 2006;311:17-58
pubmed: 17048704
Anticancer Res. 2013 Dec;33(12):5495-500
pubmed: 24324087
Oncoimmunology. 2016 Oct 18;5(11):e1232237
pubmed: 27999747
Int J Gastrointest Cancer. 2002;32(1):1-6
pubmed: 12630764
Nature. 2015 Mar 19;519(7543):366-9
pubmed: 25762141
Cancer. 2017 Aug 15;123(16):3061-3072
pubmed: 28411378
Nat Rev Cancer. 2008 May;8(5):351-60
pubmed: 18418403
Eur J Immunol. 1997 Dec;27(12):3135-42
pubmed: 9464798
Clin Transl Oncol. 2019 Jun;21(6):721-728
pubmed: 30374838
Oncoimmunology. 2014 Jan 1;3(1):e27622
pubmed: 24804161
Hepatogastroenterology. 2001 Mar-Apr;48(38):347-51
pubmed: 11379307
Curr Opin Immunol. 2001 Feb;13(1):114-9
pubmed: 11154927
J Clin Oncol. 2005 Aug 20;23(24):5779-87
pubmed: 16110035
Anticancer Res. 2010 Dec;30(12):5091-7
pubmed: 21187495
Clin Cancer Res. 2018 Dec 15;24(24):6345-6354
pubmed: 30154226
Semin Immunol. 2010 Jun;22(3):173-82
pubmed: 20409732
Oncoimmunology. 2016 Jul 8;5(9):e1207842
pubmed: 27757300
Front Immunol. 2018 Oct 01;9:2265
pubmed: 30327656
Ophthalmology. 2016 Oct;123(10):2265-7
pubmed: 27476772
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
J Exp Med. 1999 Dec 6;190(11):1669-78
pubmed: 10587357
Semin Oncol. 2012 Jun;39(3):323-39
pubmed: 22595055
Immunol Rev. 2004 Jun;199:251-63
pubmed: 15233739
Clin Cancer Res. 2009 Dec 1;15(23):7412-20
pubmed: 19934295
J Immunother. 2011 Jun;34(5):448-56
pubmed: 21577140
Cancer Res. 2018 Aug 15;78(16):4627-4641
pubmed: 29789417
J Immunol Methods. 1996 Sep 27;196(2):137-51
pubmed: 8841452
J Clin Invest. 2002 Feb;109(3):409-17
pubmed: 11828001
J Clin Oncol. 2016 Apr 20;34(12):1330-8
pubmed: 26926680
J Transl Med. 2005 Feb 08;3(1):8
pubmed: 15698481
Clin Immunol. 2010 Feb;134(2):140-7
pubmed: 19889582
J Immunol. 2004 Jun 1;172(11):6649-57
pubmed: 15153480
Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9
pubmed: 20631300
J Clin Oncol. 2005 Feb 10;23(5):999-1010
pubmed: 15598979
Cancer Immunol Immunother. 2015 Aug;64(8):1047-56
pubmed: 25982372
Oncoimmunology. 2017 Oct 4;6(12):e1386829
pubmed: 29209573
J Transl Med. 2011 Sep 13;9:151
pubmed: 21910911
Clin Cancer Res. 2017 Apr 15;23(8):1898-1909
pubmed: 28411277
J Immunol. 2005 Mar 15;174(6):3798-807
pubmed: 15749921
Clin Immunol. 2012 Mar;142(3):252-68
pubmed: 22177848
Nat Med. 2001 Jul;7(7):761-5
pubmed: 11433329
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Cancer Immunol Immunother. 2013 Sep;62(9):1499-509
pubmed: 23817721
Lancet Oncol. 2007 May;8(5):451-4
pubmed: 17466904
J Immunol Methods. 1996 Sep 27;196(2):121-35
pubmed: 8841451
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
J Transl Med. 2006 Aug 15;4:35
pubmed: 16911798
Cancer. 2005 Mar 15;103(6):1280-91
pubmed: 15693021
Eur J Cancer. 2018 Nov;104:182-187
pubmed: 30368069
J Immunol. 2001 Dec 15;167(12):7150-6
pubmed: 11739538
Sci Transl Med. 2016 Apr 13;8(334):334ra52
pubmed: 27075626
Melanoma Res. 2000 Oct;10(5):475-82
pubmed: 11095409
Transplantation. 2015 Jan;99(1):120-7
pubmed: 25050468
Anticancer Res. 2018 Apr;38(4):2217-2225
pubmed: 29599342
Neuro Oncol. 2004 Jul;6(3):236-46
pubmed: 15279716
Ther Apher Dial. 2018 Jun;22(3):266-277
pubmed: 29851270
Pancreas. 2009 Apr;38(3):e69-74
pubmed: 19276867
Cancer Immunol Immunother. 2014 Sep;63(9):959-67
pubmed: 24878889
J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8
pubmed: 26751016
Clin Cancer Res. 2012 Oct 1;18(19):5460-70
pubmed: 22896657
Anticancer Res. 2013 Sep;33(9):3855-9
pubmed: 24023319
Eur J Immunol. 2014 Nov;44(11):3413-28
pubmed: 25100611
J Immunother Cancer. 2014 Apr 15;2:9
pubmed: 27437102
J Immunother. 2008 Oct;31(8):731-41
pubmed: 18779746
J Exp Med. 1973 May 1;137(5):1142-62
pubmed: 4573839
Cancer Immunol Immunother. 2003 Jun;52(6):387-95
pubmed: 12682787
Science. 2007 Nov 16;318(5853):1108-13
pubmed: 17932254
Nat Med. 2004 Dec;10(12):1278-9; author reply 1279-80
pubmed: 15580242
Nat Med. 2004 Dec;10(12):1279; author reply 1279-80
pubmed: 15682512
Nat Med. 1996 Jan;2(1):52-8
pubmed: 8564842
J Immunother Cancer. 2019 Nov 18;7(1):309
pubmed: 31735170
Pharmacol Ther. 1994;64(3):529-64
pubmed: 7724661